 I. To determine the recommended phase 2 dose RP2D for the combination of glembatumumab vedotin and nivolumab in patients with solid tumors. Phase Ib II. To evaluate the antitumor activity of the combination in 4 expansion cohorts melanoma, uveal melanoma, GPNMB overexpressing triple negative breast cancer TNBC, other GPNMB overexpressing solid tumors as measured by overall response by Immune-Modified Response Evaluation Criteria in Solid Tumors iRECISTResponse Evaluation Criteria in Solid Tumors RECIST 1.1. Phase II 